A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.

Abstract

Tissue- and device-associated biofilm infections are important medical problems. These infections are difficult to treat due to a high-level of tolerance to antibiotics. Telavancin has been studied in several in vitro biofilm models and has demonstrated efficacy against staphylococcal and enterococcal-associated biofilm infections, including those formed by methicillin-resistant Staphylococcus aureus. Telavancin was effective against the difficult-to-treat vancomycin- and glycopeptide-intermediate strains of S. aureus in these models. Furthermore, the efficacy of telavancin has been evaluated in several biofilm-related in vivo models, including osteomyelitis, endocarditis and device-associated infections in rabbits. Overall, telavancin exhibited similar or greater efficacy than vancomycin and other comparators in these animal models and maintained activity against vancomycin-intermediate and daptomycin nonsusceptible strains of S. aureus.

• Authors: Cynthia Chan, Thomas C Hardin, Jennifer I Smart
• Journal: Future microbiology (Future Microbiol) Vol. 10 Issue 8 Pg. 1325-38 ( 2015) ISSN: 1746-0921 [Electronic] England
• PMID: 26083676 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Aminoglycosides
• Anti-Bacterial Agents
• Lipoglycopeptides
• telavancin

Topics

• Aminoglycosides (pharmacology, therapeutic use)
• Animals
• Anti-Bacterial Agents (therapeutic use)
• Biofilms (drug effects, growth & development)
• Disease Models, Animal
• Endocarditis, Bacterial (drug therapy)
• Enterococcus (drug effects)
• Lipoglycopeptides
• Methicillin-Resistant Staphylococcus aureus (drug effects)
• Microbial Sensitivity Tests
• Osteomyelitis (drug therapy)
• Staphylococcal Infections (drug therapy)
• Staphylococcus aureus (drug effects)